Revumenib
Brand names: Revuforj Ā· Active ingredient: Revumenib Citrate
In short: Relapsed or Refractory Acute Leukemia REVUFORJ is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation as determined by an FDA-authorized test in adult and pediatric patients 1 year and older. REVUFORJ is indicated for the
What is Revumenib used for?
Relapsed or Refractory Acute Leukemia
REVUFORJ is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation as determined by an FDA-authorized test in adult and pediatric patients 1 year and older.
REVUFORJ is indicated for the treatment of relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation [see Dosage and Administration (2.1), Clinical Pharmacology (12.1), and Clinical Studies (14.1)] in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.
ā Boxed warning (FDA's strongest warning)
Differentiation syndrome, which can be fatal, has occurred with REVUFORJ. Signs and symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and renal dysfunction. If differentiation syndrome is suspected, immediately initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.
[see
Dosage and Administration (2.3
)
,
Warnings and Precautions (5.1)
, and
Adverse Reactions (6.1)
]
.
QTc prolongation and Torsades de Pointes have occurred in patients receiving REVUFORJ. Correct hypokalemia and hypomagnesemia prior to and during treatment. Do not initiate REVUFORJ in patients with QTcF > 450 msec. If QTc interval prolongation occurs, interrupt, reduce, or permanently discontinue REVUFORJ. [see
Dosage and Administration (2.3)
,
Warnings and Precautions (5.2)
, and
Adverse Reactions (6.1)
]
Revumenib dosage
Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Select patients for treatment with REVUFORJ based on the presence of a KMT2A translocation
. Information on FDA authorized tests for the detection of a KMT2A translocation to determine eligibility for treatment is available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN240067
Relapsed or Refractory Acute Myeloid Leukemia with an NPM1 mutation
Select patients for treatment with REVUFORJ based on the presence of an NPM1 mutation
. An FDA-approved companion diagnostic for the detection of an NPM1 mutation is not currently available.
The recommended dosage of REVUFORJ varies by patient weight and concomitant use of strong CYP3A4 inhibitors. See Table 1 for the recommended dosage for patients 1 year and older. Do not start REVUFORJ until the WBC is reduced to less than 25 Gi/L. Continue REVUFORJ until disease progression or unacceptable toxicity. For patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response.
*See Table 2 for the total tablet dosage by BSA (body surface area) for patients weighing less than 40 kg.
Patient Weight | Without Strong CYP3A4 Inhibitors | With Strong CYP3A4 Inhibitors
40 kg or more | 270 mg orally twice daily | 160 mg orally twice daily
Less than 40 kg | 160 mg/m2 orally twice daily* | 95 mg/m2 orally twice daily*
* If needed, attain the desired dose by combining different strengths of REVUFORJ tablets.
BSA (m2) | REVUFORJ Dosage for 160 mg/m2 | REVUFORJ Dosage for 95 mg/m2
1.4 | 220 mg twice daily | 135 mg twice daily
1.3 | 220 mg twice daily | 135 mg twice daily
1.2 | 185 mg twice daily | 110 mg twice daily
1.1 | 185 mg twice daily | 110 mg twice daily
1 | 160 mg twice daily | 100 mg twice daily
0.9 | 135 mg twice daily | 75 mg twice daily
0.8 | 135 mg twice daily | 75 mg twice daily
0.7 | 110 mg twice daily | 50 mg twice daily
0.6 | 100 mg twice daily | 50 mg twice daily
0.5 | 75 mg twice daily | 50 mg twice daily
0.4 | 50 mg twice daily | 25 mg twice daily
If the strong CYP3A4 inhibitor is discontinued, increase the REVUFORJ dose after at least 5 half-lives of the strong CYP3A4 inhibitor to the recommended dosage without strong CYP3A4 inhibitors (Table 1).
Concurrent use of standard intrathecal chemotherapy prophylaxis is recommended for patients with risk of central nervous system relapse.
Administration:
Correct hypokalemia, hypomagnesemia, and other electrolyte abnormalities prior to treatment.
Administer REVUFORJ twice daily fasted or with a low-fat meal (e.g., meals with approximately 400 calories, 25% or less fat).
Administer REVUFORJ orally around the same time each day.
Advise patients to swallow tablets whole and to not cut or chew tablets. ā¦
How to take Revumenib ā instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide) and Instructions for Use.
Differentiation Syndrome
Advise patients of the risks of developing differentiation syndrome as early as 3 days after the start of therapy and during treatment. Ask patients to immediately report any symptoms suggestive of differentiation syndrome, such as fever, cough or difficulty breathing, rash, low blood pressure, rapid weight gain, swelling of their arms or legs, or decreased urinary output, to their healthcare provider for further evaluation
.
Prolonged QT Interval and Torsades de Pointes
Advise patients to consult their healthcare provider immediately if they feel faint, lose consciousness, or have signs or symptoms suggestive of arrhythmia. Advise patients with a history of hypokalemia or hypomagnesemia of the importance of monitoring their electrolytes .
Embryo-Fetal Toxicity
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to notify their healthcare provider of a known or suspected pregnancy [see
Warnings and Precautions (5.3)
and
Use in Specific Populations (8.1)
]. ā¦
Warnings & precautions
Do not take this medicine if: None.
REVUFORJ can cause fatal or life-threatening differentiation syndrome (DS). Symptoms of differentiation syndrome, including those seen in patients treated with REVUFORJ, include fever, dyspnea, hypoxia, peripheral edema, pleuropericardial effusion, acute renal failure, rash, and/or hypotension.
In clinical trials, DS occurred in 60 (25%) of 241 patients treated with REVUFORJ at the recommended dosage for relapsed or refractory acute leukemia
. Among those with a KMT2A translocation, DS occurred in 33% of patients with acute myeloid leukemia (AML), 33% of patients with mixed-phenotype acute leukemia (MPAL), and 9% of patients with acute lymphoblastic leukemia (ALL); DS occurred in 18% of patients with NPM1 mutated AML. DS was Grade 3 or 4 in 12% of patients and fatal in two patients. The median time to initial onset was 9 days (range 3-41 days). Some patients experienced more than 1 DS event. Treatment interruption was required for 7% of patients, and treatment was withdrawn for 1%.
Reduce the white blood cell count (WBC) to less than 25 Gi/L prior to starting REVUFORJ. If DS is suspected, immediately initiate treatment with systemic corticosteroids (e.g., dexamethasone 10 mg intravenously every 12 hours in adults or dexamethasone 0.25 mg/kg/dose intravenously every
12 hours in pediatric patients weighing less than 40 kg) for a minimum of 3 days and until resolution of signs and symptoms. Institute supportive measures and hemodynamic monitoring until improvement. Interrupt REVUFORJ if severe signs and/or symptoms persist for more than 48 hours after initiation of systemic corticosteroids, or earlier if life-threatening symptoms occur such as pulmonary symptoms requiring ventilator support. Restart steroids promptly if DS recurs after tapering corticosteroids . ā¦
Revumenib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Differentiation Syndrome
QTc Interval Prolongation and Torsades de Pointes
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of REVUFORJ reflects exposure in 241 patients (207 adult and 34 pediatric patients) with relapsed or refractory (R/R) acute leukemia with a KMT2A translocation or an NPM1 mutation treated with REVUFORJ at a dose approximately equivalent to 160 mg in adults orally twice daily with a strong CYP3A4 inhibitor . The median duration of exposure to REVUFORJ was 2.5 months (range < 1 to 40 months), and 10% of patients were exposed for more than 6 months.
Fatal adverse reactions occurred in 9 (4%) patients who received REVUFORJ, including 4 with sudden death, 2 with differentiation syndrome, 2 with hemorrhage, and 1 with cardiac arrest. Serious adverse reactions were reported in 184 (76%) patients. The most frequent serious adverse reactions (ā„ 10%) were infection (29%), febrile neutropenia (20%), bacterial infection (15%), differentiation syndrome (13%), and hemorrhage (11%).
Adverse reactions leading to dose interruption occurred in 49% of patients. ā¦
Drug interactions
Strong CYP3A4 Inhibitors
If concomitant use of strong CYP3A4 inhibitors is required, reduce the REVUFORJ dosage .
Revumenib is primarily metabolized by CYP3A4 . Concomitant use with a strong CYP3A4 inhibitor increases revumenib systemic exposure , which may increase the risk of REVUFORJ adverse reactions.
Strong or Moderate CYP3A4 Inducers
Avoid concomitant use with strong or moderate CYP3A4 inducers.
Revumenib is primarily metabolized by CYP3A4 . Concomitant use with a strong or moderate CYP3A4 inducer may decrease revumenib and increase M1 systemic exposure , which may reduce REVUFORJ efficacy or increase the risk of QT prolongation associated with the M1 metabolite.
Drugs that Prolong QTc Interval
Avoid concomitant use of REVUFORJ with other drugs with a known potential to prolong QTc interval. If concomitant use cannot be avoided, obtain ECGs when initiating, during concomitant use, and as clinically indicated . Withhold REVUFORJ if the QTc interval is greater than 480 msec. Restart REVUFORJ after the QTc interval returns to less than or equal to 480 msec .
REVUFORJ causes QTc interval prolongation . ā¦
About this medicine
REVUFORJ contains revumenib, a menin inhibitor. Revumenib is present as revumenib citrate hydrate with a chemical name of benzamide, N-ethyl-2-[[4-[7-[[trans-4- [(ethylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-5-fluoro-N-[1- methylethyl]-, 2-hydroxypropane-1,2,3-tricarboxylic acid, hydrate (1:1:1). The molecular formula is C32H47FN6O4SāC6H8O7āH2O with a molecular weight 840.96 g/mol.
Revumenib citrate hydrate is a white to faint pink solid. Revumenib citrate hydrate is soluble at pH 1.2 and 6.8, and sparingly soluble at pH 4.5.
The chemical structure is shown in Figure 1.
Figure 1: Chemical structure of Revumenib Citrate
REVUFORJ is available as tablets for oral use.
Each 25 mg strength tablet contains 25 mg revumenib, equivalent to 33.4 mg revumenib citrate, and the following inactive ingredients: microcrystalline cellulose, dicalcium phosphate, crospovidone, hypromellose, sodium bicarbonate, hydrophobic colloidal silica, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and red iron oxide. ā¦
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 6eb3cdbc-0e74-477d-82d6-3bb172d3f63f. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate